Back to Search Start Over

Effectiveness of Intensive Versus Minimalist Follow-Up Regimen on Survival in Patients with Endometrial Cancer (TOTEM Study): A Randomized, Pragmatic, Parallel Group, Multicenter Trial

Authors :
Zola, P
Ciccone, G
Piovano, E
Fuso, L
Di Cuonzo, D
Castiglione, A
Pagano, E
Peirano, E
Landoni, F
Sartori, E
Narducci, F
Bertetto, O
Ferrero, A
Zola, Paolo
Ciccone, Giovannino
Piovano, Elisa
Fuso, Luca
Di Cuonzo, Daniela
Castiglione, Anna
Pagano, Eva
Peirano, Elena
Landoni, Fabio
Sartori, Enrico
Narducci, Fabrice
Bertetto, Oscar
Ferrero, Annamaria
Zola, P
Ciccone, G
Piovano, E
Fuso, L
Di Cuonzo, D
Castiglione, A
Pagano, E
Peirano, E
Landoni, F
Sartori, E
Narducci, F
Bertetto, O
Ferrero, A
Zola, Paolo
Ciccone, Giovannino
Piovano, Elisa
Fuso, Luca
Di Cuonzo, Daniela
Castiglione, Anna
Pagano, Eva
Peirano, Elena
Landoni, Fabio
Sartori, Enrico
Narducci, Fabrice
Bertetto, Oscar
Ferrero, Annamaria
Publication Year :
2022

Abstract

PURPOSEIn the absence of clear evidence from randomized trials, the intensity of follow-up regimens after surgical treatment of endometrial cancer is highly variable in clinical practice. To reduce this uncertainty, we conducted a randomized trial to test whether an intensive (INT) versus a minimalist (MIN) follow-up regimen improves overall survival (OS) in patients undergoing operation for endometrial cancer.METHODSThe TOTEM study was a large, pragmatic randomized trial, conducted in 42 hospitals (in Italy and France) including patients surgically treated for endometrial cancer, in complete clinical remission, International Federation of Gynecology and Obstetrics stage I-IV. After stratification by center and risk of relapse (low or high), patients were randomly assigned (1:1) to INT or MIN hospital-based follow-up regimens. The study was powered to demonstrate an absolute improvement of 5% of the 5-year OS with the INT regimen.RESULTSIn total, 1,871 patients were randomly assigned between November 2008 and July 2018, and 1,847 patients (98.7%) were available for the final analysis (60% low risk). After a median follow-up of 69 months, the 5-year OS was 90.6% in the INT and 91.9% in the MIN arms (hazard ratio, 1.13, 95% CI, 0.86 to 1.50, P =.380). No differences in OS were found in subgroup analyses considering age, cancer treatment, risk of relapse, and degree of adherence of the center to the scheduled follow-up. The probability of detecting a relapse was slightly higher in the INT arm (hazard ratio, 1.17; 95% CI, 0.92 to 1.48; P =.194).CONCLUSIONAn INT follow-up in endometrial cancer-treated patients does not improve OS, even in high-risk patients. According to available evidence, there is no need to routinely add vaginal cytology, laboratory, or imaging investigations to the MIN regimens used in this trial.

Details

Database :
OAIster
Notes :
STAMPA, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1343244655
Document Type :
Electronic Resource